Boston Strategic Partners, Inc. is utilizing Electronic Health Record Data to analyze hospital treated sepsis

News provided by

Boston Strategic Partners, Inc.

Aug 31, 2017, 07:00 ET


Boston, MA (PRWEB) August 31, 2017 -- Boston Strategic Partners, Inc. (BSP), a life-sciences and healthcare consulting firm is utilizing its extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ to provide in-depth analysis of sepsis patients characteristics, medication management, costs and laboratory testing. In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. BSP has access to real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals and health systems across the US, representing nearly 16% of the US population.

30% of all hospital discharges involve treatment of infectious organisms. Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.

Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. From 2010-2015, drug-resistant organisms caused an astonishing 40% of bacterial sepsis infections. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.
BSP provides quantitative, objective data using real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.

Areas of focus:
• Acute Myocardial Infarction
• Antibiotic resistance
• Chronic Kidney Disease (CKD)
• Chronic Obstructive Pulmonary Disease (COPD)
• Extrinsic Asthma
• Hip and knee surgery
• Hypertension
• Influenza (and resulting complications)
• Obesity
• Osteoarthritis
• Schizophrenia
• Stroke
• Type 2 Diabetes (and resulting complications)

For more information about Boston Strategic Partners, Inc. and our data analysis reports visit: http://www.bostonsp.com/reports.

About BSP
Founded in 2003, Boston Strategic Partners, Inc. is a dedicated healthcare and life sciences company. We offer five different types of services:
• Business & Clinical Strategy
• Health Economics & Outcomes Research (HEOR)
• Medical Communications
• Regulatory Strategy
• Financial Advisory

For more information or to schedule a meeting with our team, please email us at info(at)bostonsp(dot)com

Fred Peyerl, Boston Strategic Partners, Inc., http://www.bostonsp.com, +1 617-446-3440, [email protected]